Cartherics

Executive Summary

Cartherics is an Australian preclinical biotech developing off-the-shelf allogeneic CAR-NK cell and extracellular vesicle (EV) immunotherapies for high-impact women's diseases, including ovarian cancer, triple-negative breast cancer, and endometriosis. The company's platform combines gene-edited CAR-NK cells and EVs to create scalable, ready-to-use treatments that aim to overcome the limitations of autologous cell therapies. Founded in 2016 and based in Notting Hill, Victoria, Cartherics has built a team of 50-200 employees and is advancing its lead candidates toward the clinic. With a focus on high unmet medical needs in women's health, the company positions itself as a pioneer in allogeneic immunotherapy, leveraging cutting-edge gene editing and EV technology to deliver potentially transformative therapies. Preclinical data to date suggests robust anti-tumor activity and favorable safety profiles, supporting an expected progression to IND-enabling studies. The company's private status and preclinical stage represent both opportunity and risk, with significant upside if clinical translation succeeds.

Upcoming Catalysts (preview)

• Q4 2026IND filing for lead CAR-NK candidate in ovarian cancer40% success
• Q2 2026Publication of preclinical efficacy data in triple-negative breast cancer70% success
• H2 2026Series B financing or partnership deal for EV platform55% success